Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Mononuclear Cell Therapy in Muscular Dystrophy
NCT02241928Phase 1Withdrawn
- Sponsor
- NeuroGen Brain & Spine Institute
- Start
- Jan 2009
- Primary completion
- Dec 2018
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous bone marrow-derived mononuclear cell in muscular dystrophy (MD), sponsored by NeuroGen Brain & Spine Institute. Primary endpoint: Manual Muscle Testing at 1 year. Planned start Jan 2009; status: withdrawn.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
muscular dystrophy (MD)
Beyond the preview
Go deeper on NCT02241928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02241928.